Clinical trials: Latent Autoimmune Diabetes in Adults
Diabetes, Autoimmune
Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)
Randomized, double-blind, parallel-group study to evaluate safety and efficacy of multiple subcutaneous doses of DiaPep277 in patients with Latent Autoimmune Diabetes in Adults (LADA).
- Trial name
- NCT00058981
- Testing
- DiaPep277
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- DeveloGen Israel, Ltd.
Latent Autoimmune Diabetes in Adult (LADA)
Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune Diabetes in Adult (LADA).
- Trial name
- NCT00456027
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 17 sites in Sweden
- Volunteers
- 160 people
- Sponsor
- Diamyd Therapeutics AB